Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021

3 years ago

New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported…

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

3 years ago

PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address…

Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

3 years ago

Nes-Ziona, Israel, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV

3 years ago

Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients,…

Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF

3 years ago

CHENGDU, China, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; Stock code: 2197.HK), a global clinical-stage biotechnology company…

Healthcare Triangle to Present at Sidoti December Virtual Microcap Conference

3 years ago

PLEASANTON, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the "Company"), a leading provider…

Science 37® Furthers Global Expansion with Capabilities in China and Russia to Advance Decentralized Clinical Trials and Accelerate Development

3 years ago

Science 37 enhances its Operating Systems, adding ability to deploy its technology platform into China and Russia and strengthening global…

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

3 years ago

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing…

Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement

3 years ago

Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of…

Aurora Spine Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

3 years ago

CARLSBAD, Calif. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB:…